Literature DB >> 11498704

[Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD].

J Gómez1, V Baños, E Simarro, M Lorenzo Cruz, J Ruiz Gómez, J Latour, E Garcia Martin, M Canteras, M Valdes.   

Abstract

Despite the advances in therapy, chronic obstructive pulmonary disease (COPD) requires frequent hospital admissions due to acute exacerbations. We carried out a prospective randomized study of two groups of patients with COPD, one (n = 54) treated with azithromycin (500 mg/day) for three days every 21 days during the winter months, and a control group (n = 40) without treatment. A statistically significant reduction in the number of acute infectious episodes (187) and hospital admissions (22) was observed in the treated group versus the control group (249 and 45, respectively). A short prophylactic treatment course with azithromycin is a good alternative in the management of patients with severe, advanced COPD, and could lead to an improvement in social and healthcare costs

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11498704

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  8 in total

1.  Azithromycin for prevention of exacerbations of COPD.

Authors:  Richard K Albert; John Connett; William C Bailey; Richard Casaburi; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Meilan K Han; Stephen C Lazarus; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Nancy E Madinger; Charlene McEvoy; Dennis E Niewoehner; Janos Porsasz; Connie S Price; John Reilly; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; George R Washko; Prescott G Woodruff; Nicholas R Anthonisen
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

Review 2.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

3.  Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects.

Authors:  T Pene Dumitrescu; T Anic-Milic; K Oreskovic; J Padovan; K L R Brouwer; P Zuo; V D Schmith
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

4.  Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis.

Authors:  Wentao Ni; Xiaodi Shao; Xuejiu Cai; Chuanqi Wei; Junchang Cui; Rui Wang; Youning Liu
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 5.  Use of azithromycin in the treatment of acute exacerbations of COPD.

Authors:  Aaron P Milstone
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 6.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

7.  Antibiotics for exacerbations of chronic obstructive pulmonary disease.

Authors:  Daniela J Vollenweider; Anja Frei; Claudia A Steurer-Stey; Judith Garcia-Aymerich; Milo A Puhan
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29

Review 8.  Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation.

Authors:  Salud Santos; Alicia Marin; Joan Serra-Batlles; David de la Rosa; Ingrid Solanes; Xavier Pomares; Marta López-Sánchez; Mariana Muñoz-Esquerre; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.